Barclays PLC increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 53.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,456 shares of the company's stock after buying an additional 25,878 shares during the period. Barclays PLC owned 0.15% of Amphastar Pharmaceuticals worth $3,613,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. TD Asset Management Inc increased its stake in shares of Amphastar Pharmaceuticals by 67.4% during the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock worth $67,663,000 after purchasing an additional 680,976 shares during the last quarter. Boston Trust Walden Corp acquired a new position in Amphastar Pharmaceuticals during the third quarter worth approximately $26,189,000. Millennium Management LLC raised its stake in Amphastar Pharmaceuticals by 84.6% in the second quarter. Millennium Management LLC now owns 738,748 shares of the company's stock valued at $29,550,000 after buying an additional 338,653 shares during the period. Epoch Investment Partners Inc. raised its stake in Amphastar Pharmaceuticals by 35.1% in the second quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock valued at $43,154,000 after buying an additional 280,390 shares during the period. Finally, Marshall Wace LLP acquired a new stake in shares of Amphastar Pharmaceuticals in the second quarter valued at approximately $9,085,000. 65.09% of the stock is owned by institutional investors.
Insider Activity
In other news, EVP Yakob Liawatidewi sold 5,214 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the completion of the sale, the executive vice president now directly owns 74,938 shares in the company, valued at approximately $3,900,522.90. The trade was a 6.51 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO William J. Peters sold 7,426 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $52.05, for a total value of $386,523.30. Following the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at $4,898,061.15. This represents a 7.31 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 41,533 shares of company stock valued at $1,987,482. 27.10% of the stock is owned by company insiders.
Amphastar Pharmaceuticals Stock Performance
Shares of NASDAQ AMPH traded down $0.02 during trading hours on Monday, reaching $39.12. 543,040 shares of the stock were exchanged, compared to its average volume of 415,791. The firm has a market capitalization of $1.88 billion, a price-to-earnings ratio of 13.04, a P/E/G ratio of 0.87 and a beta of 0.78. The stock's fifty day simple moving average is $46.46 and its 200 day simple moving average is $44.57. The company has a debt-to-equity ratio of 0.82, a quick ratio of 2.61 and a current ratio of 3.43. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on AMPH shares. Wells Fargo & Company initiated coverage on Amphastar Pharmaceuticals in a report on Friday, November 22nd. They set an "equal weight" rating and a $55.00 target price on the stock. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, November 1st. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $60.33.
Check Out Our Latest Analysis on AMPH
Amphastar Pharmaceuticals Company Profile
(
Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Featured Stories
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.